114 related articles for article (PubMed ID: 35439627)
1. Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines.
Liu R; Yang H; Chen Z; Zhou K; Shi Q; Li J; Huang Y; Huang X; Li Y
Bioorg Chem; 2022 Jul; 124():105803. PubMed ID: 35439627
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
3. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel benzimidazole derivatives as potent p300 bromodomain inhibitors with anti-proliferative activity in multiple cancer cells.
Chen Z; Li J; Yang H; He Y; Shi Q; Chang Q; Liu R; Huang X; Li Y
Bioorg Med Chem; 2022 Jul; 66():116784. PubMed ID: 35569250
[TBL] [Abstract][Full Text] [Related]
5. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.
Xu H; Luo G; Wu T; Hu J; Wang C; Wu X; Zhang Y; Xu Y; Xiang Q
Biochem Biophys Res Commun; 2022 Oct; 623():17-22. PubMed ID: 35868068
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
Xiong Y; Zhang M; Li Y
Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
Huang L; Li H; Li L; Niu L; Seupel R; Wu C; Cheng W; Chen C; Ding B; Brennan PE; Yang S
J Med Chem; 2019 May; 62(9):4526-4542. PubMed ID: 30998845
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
[TBL] [Abstract][Full Text] [Related]
16. Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes.
Chen J; Ghazawi FM; Li Q
Epigenetics; 2010 Aug; 5(6):509-15. PubMed ID: 20505343
[TBL] [Abstract][Full Text] [Related]
17. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
18. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
[TBL] [Abstract][Full Text] [Related]
19. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]